Theodore Hong, MD
Enriched profileDirector, Gastrointestinal Radiation Oncology Service; Associate Clinical Director, Department of Radiation Oncology, Massachusetts General Hospital; Professor of Radiation Oncology, Harvard Medical School · Massachusetts General Hospital
Theodore Hong is Director, Gastrointestinal Radiation Oncology Service; Associate Clinical Director, Department of Radiation Oncology, Massachusetts General Hospital; Professor of Radiation Oncology, Harvard Medical School at Massachusetts General Hospital. OpenAlex indexes 953 publications with 23,847 citations (h-index 70); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Radiation Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Theodore Hong, MD, is Director, Gastrointestinal Radiation Oncology Service at Massachusetts General Hospital. The public record shows 953 publications with 23,847 citations (h-index 70), centered on Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 5 companies, 2 NIH-funded awards (2016–2025).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Pancreatic and Hepatic Oncology Research
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 26 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 243.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer
Sponsor: Massachusetts General Hospital
- Nivolumab+Ipilimumab+RT in MSS mCRC
Sponsor: Massachusetts General Hospital
- Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
Sponsor: Massachusetts General Hospital
Industry payments
Updated 27 Aug 2026
5 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- IBA Proton Therapy, Inc.Program year20241 payment
- AstraZeneca Pharmaceuticals LPProgram year20231 payment
- Novocure Inc.Program year20221 payment
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Antidiarrheal microorganisms100%Creon100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
2 NIH research awards on record, funded 2016–2025 per NIH RePORTER. The latest:
- Integrating patient-specific clinical and biological factors towards individualizing utilization of proton and photon radiation therapy.
Massachusetts General Hospital
FY2025$2,749,617P01CA261669 - Integrating patient-specific clinical and biological factors towards individualizing utilization of proton and photon radiation therapy.
Massachusetts General Hospital
FY2024$2,613,084P01CA261669
Congress activity
Updated 27 Aug 2026
250 congress contributions (2004–2026) across AACR, ASCO, ASTRO, SABCS per OpenAlex. The most recent:
- Alliance A022104/NRG-GI010, a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer (LARC): The Janus Rectal Cancer trial.
ASCO Annual Meeting
ASCO2026Co-author - NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America).
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors.
Clinical cancer research
Article2026 - Reply to: Yttrium-90 Radioembolization Provides Durable Local Control and Definitive Radiation Therapy.
Journal of clinical oncology
Article2026 - Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters.
Journal of clinical oncology
Article2026 - Neoadjuvant stereotactic body radiation therapy plus immune therapy favorably remodels the hepatocellular carcinoma tumor microenvironment.
Clinical cancer research
Article2026 - Challenges Remaining for Yttrium-90 Radioembolization: The Case for Standardized Dosimetry and Comparative Local Control Analyses in Liver Tumors.
Journal of clinical oncology
Article2025
Most-cited works
by citation count (OpenAlex)- 01Pancreatic Adenocarcinoma2,344 citations2014
- 02
- 03
- 04Treatment of Metastatic Colorectal Cancer: ASCO Guideline614 citations2022
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/theodore-hong-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/ted-hong-a82764111
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Theodore-Hong
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/MGHCC/videos/the-importance-of-teamwork-and-a-multidisciplinary-approach-to-cancer-care-with-/200492497681559
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - LinkedIn
LinkedIn: Ted Hong, MD - Vice Chair of Integration, Radiation Oncology (BIDMC/incoming)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hmfphysicians.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- Chair
National Cancer Institute Rectal-Anal Cancer Task Force
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hmfphysicians.org ↗
Awards & honors
honors on the public record- The One Hundred Honoree
Massachusetts General Hospital Cancer Center (annual recognition of leaders in the fight against cancer)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giving.massgeneral.org ↗
Secondary affiliations
appointments beyond the home institution- Incoming Vice Chair of Integration and Operations
Department of Radiation Oncology, Beth Israel Deaconess Medical Center (BIDMC), effective September 2026
2026provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hmfphysicians.org ↗ - Dana-Farber/Harvard Cancer Center
Co-Chair, Gastrointestinal Research Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
Media & interviews
press, podcasts and appearances- Video interview
Mass General Cancer Center: discusses multidisciplinary GI cancer care planning and teamwork
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneral.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital